High celecoxib-loaded nanoparticles prepared by a vibrating nozzle device

Journal of Microencapsulation

Volumn 26, Issue 8, 2009, Pages 748-759

  Zvonar, Alenka ^a   Kristl, Julijana ^a   Kerč, Janez ^b   Grabnar, Pegi Ahlin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b Lek dd   (Slovenia)

Author keywords

Celecoxib; Drug carriers; Encapsulator; Hydrophobic drug; PLGA; Preparation technique

Indexed keywords

CELECOXIB; NANOPARTICLE; POLYGLACTIN; POLYLACTIC ACID; POLYVINYL ALCOHOL;

ARTICLE; CONTROLLED STUDY; DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; IN VITRO STUDY; PARTICLE SIZE; THERMAL ANALYSIS; VIBRATING NOZZLE DEVICE; X RAY DIFFRACTION;

CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; NANOPARTICLES; PYRAZOLES; SULFONAMIDES;

EID: 70449411954     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040802584402     Document Type: Article

References (25)

1. Ahlin P, Kristl J, Kristl A, Vrečer F. 2002. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 239:113-120.
2. Allemann E, Leroux JC, Gurnay R, Doelker E. 1993. In vitro extendedrelease properties of drug-loaded poly (D,L-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 10:1732-1737.
3. Alonso MJ. 1996. Nanoparticulate drug carrier technology. In: Lieberman HA, Rieger MM, Benker GS, editors. Pharmaceutic dosage forms: Disperse systems. Vol.1, New York: Marcel Dekker. pp 203-242.
4. Arangoa MA, Companero MA, Renedo MJ, Ponchet G, Irache JM. 2001. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res 18:1521-1527.
5. Budhian A, Siegel SJ, Winey KI. 2007. Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm 336:367-375.
6. Dong Y, Feng SS. 2004. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25:2843-2849.
7. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. 1989. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1-R4.
8. Galindo-Rodr?́guez SA, Puel F, Briançon S, Allémann E, Doelker E, Fessi H. 2005. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. Eur J Pharm Sci 25:357-367.
9. Gorner T, Gref R, Michenot D, Sommer F, Tran MN, Dellacherie E. 1999. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J Contr Rel 57:259-268.
10. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. 1999. PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug. J Contr Rel 57:171-185.
11. Hariharan S, Bhardwaj V, Bala HI, Sitterberg J, Bakowsky U, Ravi Kumar MNV. 2006. Design of estradiol loaded PLGA nanoparticulate formulations: A potential oral delivery system for hormone therapy. Pharm Res 23:184-195.
12. Homar M, Ubrich N, El Ghazouani F, Kristl J, Kerč J, Maincent P. 2007. Influence of polymers on the bioavailability of microencapsulated celecoxib. J Microencapsulation 24:621-633.
13. Jain RA. 2000. The manufacturing techniques of various drug-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490.
14. Jeon HJ, Jeong YI, Jang MK, Park YH, Nah JW. 2000. Effect of solvent on the preparation of surfactant-free poly(-lactide-co glycolide) nanoparticles and norfloxacin release characteristics. Int J Pharm 207:99-108.
15. Konan YN, Gurny R, Allemann E. 2002. Preparation and characterization of sterile and freeze-dried sub-200nm nanoparticles. Int J Pharm 233:239-252.
16. Kristl J, Allemann E, Gurny R. 1996. Formulation and evaluation of zincphthalocyanine loaded poly(D,L-lactic acid) nanoparticles. Acta Pharm 46:1-12.
17. Lamprecht A, Schafer U, Lehr CM. 2001. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflammed colonic mucosa. Pharm Res 18:788-793.
18. Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, et al. 1995. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci 84:1387-1391.
19. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. 2004. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93:1804-1814.
20. Piñón-Segundo E, Ganem-Quintanar A, Alonso-Pérez V, Quintanar- Guerrero D. 2005. Preparation and characterization of triclosan nanoparticles for periodontal treatment. Int J Pharm 294:217-232.
21. Pluess-Wenzinger R, Widmer F, Heinzen C, Brandenberger H. 2000. Method and device for capsulating microbal, plant and animal cells or biological and chemical substances. EP1062032. Inotech AG.
22. Radwan MA. 1995. In vitro evaluation of polyisobutylcyanoacrylate nanoparticles as a controlled drug carrier for theophylline. Drug Dev Ind Pharm. 22:2371-2375.
23. Sahana DK, Mittal G, Bhardway V, Ravi Kumar MNV. 2008. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behaviour in vitro and in vivo using estradiol as a model drug. J Pharm Sci 97:1530-1542.
24. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. 2002. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Contr Rel 82:105-114.
25. Zeisser-Labouèbe M, Lange N, Gurny R, Delie F. 2006. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm 326:174-181